TERI
Teriparatide
Recombinant human parathyroid hormone, residues 1 to 34 — the N-terminal third of the 84-residue hormone. That fragment carries the full activity of the intact hormone at the PTH1 receptor; the remaining 50 residues are not required for receptor binding.
Teriparatide has 145 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 22,064 planned or enrolled participants across the 132 studies that published a figure. An FDA-approved product contains Teriparatide — TERIPARATIDE (ANDA211097). 1,785 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Teriparatide; the registry search is fuzzy, so every match is re-checked. None of this says whether Teriparatide works or is safe.
FDA status
Approved
Human studies
145
Furthest phase
Phase 4
Papers, 10 yr
1,785
Readership
2,243
monthly average, Feb–Jul 2026
Tracking since 2026-08-02 · About this data
What has actually been tested in humans
An approved product exists
145
Registered human studies
Phase 4
Furthest phase reached
22,064
Planned or enrolled participants, across 132 studies that published a figure
Approved
FDA-approved product — TERIPARATIDE
182 loose registry matches were checked and 145 confirmed — 37 named something else and were discarded. We count a study only when Teriparatide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Teriparatide is, and what it has been studied for
Teriparatide is classified by ChEMBL as a protein, and appears in trial registrations under 1-34-HUMAN PTH and LY 333334. Its FDA substance identifier is 10T9CSU89I.
Across 145 registered trials, it has been studied in Osteoporosis, Osteoporosis, Postmenopausal, Postmenopausal Osteoporosis and Osteoporotic Fractures. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Massachusetts General Hospital among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Teriparatide reached Phase 4 across 145 registered trials.
An FDA-approved product contains Teriparatide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Teriparatide?
Papers published each year that name Teriparatide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 200 | 7 | Yes |
| 2018 | 179 | 2 | Yes |
| 2019 | 202 | 6 | Yes |
| 2020 | 210 | 3 | Yes |
| 2021 | 230 | 6 | Yes |
| 2022 | 199 | 2 | Yes |
| 2023 | 178 | 3 | Yes |
| 2024 | 189 | 1 | Yes |
| 2025 | 266 | 5 | Yes |
| 2026 | 191 | 0 | No |
1,785 papers and 35 registered trials between 2017 and 2026. A paper counts when “Teriparatide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Teriparatide
1,785 indexed papers name Teriparatide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- Teriparatide
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials
- Teriparatide: a review
- Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab
- Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
- Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis
Collected 2026-08-02from PubMed, phrase-matched on “Teriparatide” in title and abstract. Run the same search.
About Teriparatide
Recombinant human parathyroid hormone, residues 1 to 34 — the N-terminal third of the 84-residue hormone. That fragment carries the full activity of the intact hormone at the PTH1 receptor; the remaining 50 residues are not required for receptor binding.
- Also known as
- PTH (1-34) · LY333334
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.